We'll know more about the company's medium-term prospects by the end of the year.

CRISPR Therapeutics stock snapshot and recent performance CRISPR Therapeutics (CRSP) has drawn investor attention after its ...

With an approved treatment in commercial stages and new drug candidates generating clinical trial results, this biotech has attracted a big Investor.

Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

For the first time, a team of researchers from Stellenbosch University (SU) and the Agricultural Research Council has ...

Key market opportunities include advancements in research, medicine, diagnostics, and biotechnology through CRISPR. There is potential for innovative solutions and ethical exploration in gene editing, ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

Cathie Wood and Wall Street don't always agree. The chief executive officer of Ark Invest has been more bullish on Tesla, for example, than the general analyst community and has taken advantage of ...

The latest health news highlights Gerresheimer's rejection of a takeover bid from Silgan, researchers' progress with CRISPR for Down syndrome, Eli Lilly's obesity pill traction, Trump's push on ...

CRISPR Therapeutics is targeting multiple difficult-to-treat diseases with several candidates. The company's shares could soar if it delivers consistent clinical and regulatory progress. However, the ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...